title: Characterization of cutaneous vascular permeability induced by platelet-activating factor in guinea pigs and rats and its inhibition by a platelet-activating factor receptor antagonist.
abstract: Mechanisms of platelet-activating factor (PAF)-induced increases of cutaneous vascular permeability in guinea pigs and in rats were further explored. PAF so far is the most potent vasoactive mediator, being more than 1000-fold more potent than histamine and bradykinin in both species. In guinea pigs, there is a time delay of 5 to 10 minutes before PAF action, whereas, in the rat, the increased vasopermeability occurs immediately following the intradermal PAF injection. Relative vasoactive potencies of PAF and several structure-related analogues in both species correlate very well with their relative inhibition of the binding of 3H-PAF to specific receptor sites on isolated rabbit platelet plasma membranes and their aggregatory abilities of rabbit platelets. Furthermore, the PAF-induced cutaneous vascular permeability is inhibitable by a competitive specific PAF receptor antagonist, kadsurenone, suggesting that binding of PAF to its specific receptor site is the first step to initiate its action of increased cutaneous vascular permeability. Several pure cyclooxygenase inhibitors, including indomethacin, diflunisal, and flurbiprofen, and the dual cyclooxygenase/lipoxygenase inhibitor, BW755C, but not the histamine antagonists, inhibit the PAF-induced vasopermeability in guinea pigs. The inhibition by indomethacin or BW755C can be fully reversed by coinjection intradermally with PAF and prostaglandin E1 but not leukotriene B4. Also, prostaglandin E1 but not leukotriene B4 enhances the guinea pig in vivo response to PAF in this model. However, in rats, none of the cyclooxygenase inhibitors, histamine antagonists, or BW755C inhibit the PAF effect of cutaneous phenomena even though prostaglandin E1 also enhances the PAF potency of the increased cutaneous vascular permeability. Kadsurenone, a competitive specific receptor antagonist, inhibits both histamine- and bradykinin-induced rat cutaneous vascular permeability which suggests that PAF may be involved in the vasopermeability induced by histamine and bradykinin.
mesh_terms: D000818:Animals; D001572:Benzofurans; D001578:Benzopyrans / Q000494:pharmacology; D001665:Binding Sites / Q000187:drug effects; D001920:Bradykinin / Q000494:pharmacology; D002463:Cell Membrane Permeability / Q000187:drug effects*; D016861:Cyclooxygenase Inhibitors; D004347:Drug Interactions; D005260:Female; D006168:Guinea Pigs; D006632:Histamine / Q000494:pharmacology; D007213:Indomethacin / Q000494:pharmacology; D017705:Lignans; D010972:Platelet Activating Factor; D010974:Platelet Aggregation / Q000187:drug effects; D011817:Rabbits; D051381:Rats; D011919:Rats, Inbred Strains; D012867:Skin / Q000187:drug effects* / Q000378:metabolism; D013045:Species Specificity; D014316:Tritium
chemical_list: D001572:Benzofurans; D001578:Benzopyrans; D016861:Cyclooxygenase Inhibitors; D017705:Lignans; D010972:Platelet Activating Factor; D014316:Tritium; D006632:Histamine; C044540:kadsurenone; D001920:Bradykinin; D007213:Indomethacin